INVIVYD, INC. Other Noncash Income (Expense)
INVIVYD, INC. (IVVD) reported Other Noncash Income (Expense) of -$7.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OtherNoncashIncomeExpense · last filed 2026-08-13
- INVIVYD, INC. other noncash income (expense) for the quarter ending 2026-06-30 was $47.00K.
- INVIVYD, INC. other noncash income (expense) for the quarter ending 2026-03-31 was -$54.00K.
- INVIVYD, INC. other noncash income (expense) for the quarter ending 2025-12-31 was -$2.00K.
- INVIVYD, INC. other noncash income (expense) for the quarter ending 2025-09-30 was -$205.00K.
- INVIVYD, INC. other noncash income (expense) for fiscal 2025 was -$298.00K.
- INVIVYD, INC. other noncash income (expense) for fiscal 2024 was $0.00.
| Period end | Other Noncash Income (Expense) 3 month | Other Noncash Income (Expense) 6 month | Other Noncash Income (Expense) 9 month | Other Noncash Income (Expense) 12 month |
|---|---|---|---|---|
| 2026-06-30 | $47.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$7.00K 10-Q · filed 2026-08-13 | -$9.00K derived: sum of 3 quarters · filed 2026-08-13 | -$214.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | -$54.00K 10-Q · filed 2026-05-14 | -$56.00K derived: sum of 2 quarters · filed 2026-05-14 | -$261.00K derived: sum of 3 quarters · filed 2026-05-14 | -$352.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | -$2.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$207.00K derived: sum of 2 quarters · filed 2026-03-05 | -$298.00K derived: sum of 3 quarters · filed 2026-08-13 | -$298.00K 10-K · filed 2026-03-05 |
| 2025-09-30 | -$205.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$296.00K derived: sum of 2 quarters · filed 2026-08-13 | -$296.00K 10-Q · filed 2025-11-06 | -$296.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | -$91.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$91.00K 10-Q · filed 2026-08-13 | -$91.00K derived: sum of 3 quarters · filed 2026-08-13 | -$91.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-14 | $0.00 derived: sum of 2 quarters · filed 2026-05-14 | $0.00 derived: sum of 3 quarters · filed 2026-05-14 | |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $0.00 derived: sum of 2 quarters · filed 2026-03-05 | $0.00 10-K · filed 2026-03-05 | |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $0.00 10-Q · filed 2025-11-06 | ||
| 2024-06-30 | $0.00 10-Q · filed 2025-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |